PTGS2 and non-small cell lung carcinoma: Celecoxib, a COX-2 inhibitor, also suppressed the NF-κB-regulated COX-2 expression in patients with non-small cell lung cancer, and this inhibition was associated with a reduction in TNF-α-induced COX-2 transcription (67).